- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
argenx SE (ARGX)
The Argenx share price today is 782.20, view EBR ARGX stock exchange data. Track the latest Argenx share price with real-time updates on ARGX stock performance including market cap, day range, 52-week range and dividend yield. Access ARGX charts, earnings dates and analyst estimates to support your investment decisions.
782.20
-1.20(-0.15%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
772.80
789.20
52 wk Range
568.40
925.00
ARGX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
772.80789.20
52 wk Range
568.40925.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARGX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
1,001.47
Upside
+28.03%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
Argenx receives Investment Bank Analyst Rating Update- Investing.com
Pro
Argenx receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
13 Buy
2 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 1,001.47
(+28.03% Upside)
argenx SE Earnings Call Summary for Q3/2026
- Q3 revenue hit $1.56B, up 54% YoY, beating estimates by 6.1%; EPS of $6.95 missed forecasts by $0.07 amid increased investment spending.
- VYVGART franchise drove growth across MG and CIDP indications; U.S. sales reached $1.5B, representing 88% of total product revenue.
- Company expects five potential product launches in 2027, including pediatric MG, ocular MG, IMNM, and empasiprubart for MMN pending trial data.
- 2026 R&D and SG&A expenses projected at $4B, up 45% YoY; 2027 spending growth expected to moderate to roughly 22-23%, formal guidance coming soon.
- Operating margin reached 28% with 24% ROE; management emphasized revenue growth outpacing expenses, demonstrating operating leverage despite expansion.
Last Updated: 22-10-2026, 07:12 pm
Read Full TranscriptEarnings
Latest Release
22-10-2026
EPS / Forecast
6.97 / 7.02
Revenue / Forecast
1.56B / 1.47B
Compare ARGX to Peers and Sector
Metrics to compare | ARGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARGXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 31.9x | 27.2x | −0.3x | |
PEG Ratio | 0.80 | 0.44 | 0.00 | |
Price/Book | 6.5x | 3.6x | 2.6x | |
Price / LTM Sales | 10.3x | 4.1x | 2.9x | |
Upside (Analyst Target) | 28.1% | 44.0% | 65.5% | |
Fair Value Upside | Unlock | 5.5% | 9.5% | Unlock |
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Argenx (ARGX) Share Price Today?
The Argenx share price today is 782.20.
What is the current Argenx (ARGX) share price and day range?
As of 24-10-2026, the Argenx share price is 782.20, with a previous close of 782.20. The share price has ranged from 772.80 to 789.20 today, while the 52-week range spans from 568.40 to 925.00.
What Is the Argenx Market Cap?
As of today, Argenx market cap is 48.92B.
What Is the Argenx (ARGX) Share Price Target?
The average 12-month share price target for Argenx is 1,001.47, with a high estimate of 1179.4956708 and a low estimate of 776.66785682. 13 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +28.03% Upside potential.
What Is Argenx's Earnings Per Share (TTM)?
The Argenx EPS (TTM) is 26.64.
When Is the Next Argenx Earnings Date?
Argenx will release its next earnings report on 04-03-2027.
From a Technical Analysis Perspective, Is ARGX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Argenx Trade On?
Argenx is listed and trades on the Brussels Stock Exchange.
What Is the Stock Symbol for Argenx?
The stock symbol for Argenx is "ARGX."
How Many Times Has Argenx Stock Split?
Argenx has split 0 times.
How Many Employees Does Argenx Have?
Argenx has 1863 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.